Topical Aspirin Administration Improves Cutaneous Wound Healing in Diabetic Mice Through a Phenotypic Switch of Wound Macrophages Toward an Anti-inflammatory and Proresolutive Profile Characterized by LXA4 Release.

Autor:	Dardenne C; UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le Développement, Université Paul Sabatier, Toulouse, France., Salon M; UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le Développement, Université Paul Sabatier, Toulouse, France.; RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, Université Paul Sabatier, Toulouse, France., Authier H; UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le Développement, Université Paul Sabatier, Toulouse, France.; RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, Université Paul Sabatier, Toulouse, France., Meunier E; UMR 5089, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France., AlaEddine M; UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le Développement, Université Paul Sabatier, Toulouse, France., Bernad J; UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le Développement, Université Paul Sabatier, Toulouse, France., Bouschbacher M; URGO Group, Chenôve, France., Lefèvre L; UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le Développement, Université Paul Sabatier, Toulouse, France.; RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, Université Paul Sabatier, Toulouse, France., Pipy B; UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le Développement, Université Paul Sabatier, Toulouse, France., Coste A; UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le Développement, Université Paul Sabatier, Toulouse, France.; RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, Université Paul Sabatier, Toulouse, France.
Jazyk:	angličtina
Zdroj:	Diabetes [Diabetes] 2022 Oct 01; Vol. 71 (10), pp. 2181-2196.
DOI:	10.2337/db20-1245
Abstrakt:	Patients with diabetes present a persistent inflammatory process, leading to impaired wound healing. Since nonhealing diabetic wound management shows limited results, the introduction of advanced therapies targeting and correcting the inflammatory status of macrophages in chronic wounds could be an effective therapeutic strategy to stop the sustained inflammation and to return to a healing state. In an excisional skin injury in a diet-induced diabetic murine model, we demonstrate that topical administration of low-dose aspirin (36 μg/wound/day) improves cutaneous wound healing by increasing wound closure through the promotion of the inflammation resolution program of macrophages. This treatment increased efferocytosis of wound macrophages from aspirin-treated diabetic mice compared with untreated diabetic mice. We also show that aspirin treatment of high-fat-fed mice oriented the phenotype of wound macrophages toward an anti-inflammatory and proresolutive profile characterized by a decrease of LTB4 production. The use of diabetic mice deficient for 5-LOX or 12/15-LOX demonstrated that these two enzymes of acid arachidonic metabolism are essential for the beneficial effect of aspirin on wound healing. Thus, aspirin treatment modified the balance between pro- and anti-inflammatory eicosanoids by promoting the synthesis of proresolving LXA4 through 5-LOX, LTA4, 12/15-LOX signaling. In conclusion, the restoration of an anti-inflammatory and proresolutive phenotype of wound macrophages by the topical administration of low-dose aspirin represents a promising therapeutic approach in chronic wounds. (© 2022 by the American Diabetes Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu